Recent Share Transactions Overview
Copenhagen, Denmark – Bavarian Nordic A/S (Copenhagen: BAVA) has disclosed new share transactions involving its management team. This announcement highlights the active participation of key individuals within the company, showcasing their commitment to Bavarian Nordic's goals.
Key Executive Transactions
On the same day, two notable transactions took place, reflecting the engagement of the executive management team. Paul John Chaplin, the President and CEO, was at the forefront of one of these transactions, demonstrating leadership through his financial involvement.
Details of Paul John Chaplin's Transaction
On a specified date, Paul John Chaplin carried out a significant share transaction, categorized as the exercise of warrants. This action aligns the interests of executives with those of shareholders and signals confidence in the company’s future trajectory.
- Position: President and Chief Executive Officer
- Type of Transaction: Exercise of warrants
- Volume: 98,855 shares at a price of DKK 146.60 each
- Total Value: DKK 14,492,143.00
- Date of Transaction: 2024-09-05
- Place of Transaction: Nasdaq Copenhagen A/S
Details of Henrik Juuel's Transaction
Simultaneously, Henrik Juuel, the Executive Vice President and CFO, participated in a notable transaction that highlights his financial commitment to the company.
- Position: Executive Vice President and Chief Financial Officer
- Type of Transaction: Exercise of warrants
- Volume: 42,916 shares at DKK 146.60 each
- Total Value: DKK 6,291,486.00
- Date of Transaction: 2024-09-05
- Place of Transaction: Nasdaq Copenhagen A/S
Details of Jean-Christophe May's Transaction
Lastly, Jean-Christophe May, the Executive Vice President and Chief Commercial Officer, also engaged in a significant stock transaction, further solidifying the financial strategy of the executive team.
- Position: Executive Vice President and Chief Commercial Officer
- Type of Transaction: Exercise of warrants
- Volume: 7,039 shares at DKK 155.80 each
- Total Value: DKK 1,096,676.00
- Date of Transaction: 2024-09-05
- Place of Transaction: Nasdaq Copenhagen A/S
About Bavarian Nordic
Bavarian Nordic is a fully integrated vaccine company focused on saving lives through innovative vaccination solutions. The company has established itself as a leader in developing and supplying smallpox and mpox vaccines for government agencies, emphasizing global public health preparedness. With a diverse portfolio aimed at travelers and endemic diseases, Bavarian Nordic is committed to expanding its impact in the health sector.
Contact Information
For additional inquiries, please reach out to Rolf Sass Sørensen, Vice President of Investor Relations at Bavarian Nordic, using the following contact details:
- Email: rss@bavarian-nordic.com
- Tel: +45 61 77 47 43
For inquiries in the United States, please contact Graham Morrell at Paddock Circle Advisors:
- Email: graham@paddockcircle.com
- Tel: +1 781 686 9600
Frequently Asked Questions
What is the significance of these share transactions?
These transactions show that top executives are actively investing in their company, which reflects their confidence in its future performance.
Who are the executives involved in the recent transactions?
The transactions were carried out by Paul John Chaplin, Henrik Juuel, and Jean-Christophe May, all of whom are key members of Bavarian Nordic's leadership team.
What types of financial instruments were involved?
The transactions involved shares of Bavarian Nordic, specifically through the exercise of warrants.
How do these transactions affect shareholders?
When executives invest in their own company, it can positively influence shareholder sentiment and may impact stock performance favorably.
Where can I find more information about Bavarian Nordic?
For more detailed information, you can visit Bavarian Nordic's official website.
